Compare · MRNA vs SCLX
MRNA vs SCLX
Side-by-side comparison of Moderna Inc. (MRNA) and Scilex Holding Company (SCLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and SCLX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $61.59B, about 1342.9x SCLX ($45.9M).
- MRNA has been more active in the news (15 items in the past 4 weeks vs 5 for SCLX).
- MRNA has more recent analyst coverage (25 ratings vs 6 for SCLX).
- Company
- Moderna Inc.
- Scilex Holding Company
- Price
- -
- -
- Market cap
- $61.59B
- $45.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 15
- 5
- Recent ratings
- 25
- 6
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation
- Moderna upgraded by Argus with a new price target
- Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
- Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Latest SCLX
- Amendment: SEC Form SCHEDULE 13D/A filed by Scilex Holding Company
- Large owner Scilex Holding Co disposed of $15,755,000 worth of shares (50,000,000 units at $0.32), decreasing direct ownership by 23% to 163,766,229 units (SEC Form 4)
- SEC Form 10-Q filed by Scilex Holding Company
- JP 3E Holdings, Inc. Appoints Henry Ji, Ph.D., Stephen Ma and Jaedong Yoon to Board of Directors
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits
- Large owner Sclx Stock Acquisition Jv Llc disposed of 500,000 shares, decreasing direct ownership by 34% to 958,263 units (SEC Form 4)
- Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
- Scilex Holding Company filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group LLP